B2PRIME
10.6.2024 13:19:26 CEST | Business Wire | Press release
B2Prime, a leading global multi-asset and multi-market Prime of Prime liquidity provider, and Spotware, a premier and innovative trading platform provider, have announced a strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610848632/en/
B2Prime, a Prime of Prime multi-asset liquidity provider, and cTrader, Spotware's flagship trading platform, have established a strategic partnership to expand trading opportunities. (Graphic: Business Wire)
The cTrader platform by Spotware is renowned for its advanced features that cater to professional traders:
Clear and stunning UI → Visually appealing and comprehensive user interface with a possibility for deep customisation.
Multi-asset trading without latency → A diverse range of supported asset classes alongside lightning-fast order entry and execution.
Depth of market (DOM) → Level II pricing empowers traders to evaluate market sentiment and anticipate potential price movements with higher accuracy.
Top availability → cTrader offers cross-platform accessibility with its Desktop, Mac, Web and Mobile (iOS and Android) apps.
Advanced risk management → cTrader users are equipped with sophisticated protection tools to trade with confidence.
Algo trading solutions → Out-of-the-box ecosystem for algo trading, with cBots, indicators and plugins.
Social trading platform → cTrader Copy is an integrated platform where strategy providers and investors meet.
Nicholas Chrysochos, Executive Director of B2Prime, remarks:
"Numerous hedge funds, money managers, professional traders, algorithmic traders, systematic traders, and high-net-worth individuals have shown a keen interest in accessing our extensive liquidity pool. In response to this growing demand, we have chosen cTrader as the platform through which these clients can access our bespoke liquidity products across a wide range of jurisdictions. We are licensed by CySEC, allowing us to serve the entire EU market, and we also hold licenses in Mauritius and Seychelles. This strategic growth is part of our commitment to helping our clients excel in competitive global markets."
Currently, B2Prime has several outstanding platforms, namely OneZero, PrimeXM, now cTrader, and FIX API connectivity.
Ilia Iarovitcyn, CEO of Spotware Systems, comments:
“We are excited to continuously develop our liquidity provision network, expand the asset offering and enhance the reliability of our trading environment. Partnering with B2Prime contributes to delivering competitive pricing and an exceptional trading experience to our end users. With our cutting-edge technology and B2Prime’s strategic growth, we are confident in driving innovation and success for our clients globally.”
The collaboration between B2Prime and Spotware extends B2Prime’s range of services and significantly enhances cTrader’s liquidity offering, making it even more competitive. With a portfolio of over 200 instruments across six asset classes—FOREX, Crypto CFDs, Spot Indices, Precious Metals, Commodities, and NDFs—B2Prime offers one of the most comprehensive liquidity solutions on the market.
The company guarantees access to the deepest liquidity pools sourced from the most reputable providers, ensuring competitive spreads and swift execution. Additionally, B2Prime provides multi-currency prime margin accounts and an institutional tiered-margin approach.
Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 240+ brokers and prop firms. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610848632/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom